# Publications

## As a first author

-   Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study.\
    [*Analysis notebook*](./analysis-notebooks/report-realworld-risankizumab-belgium.html)
-   Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\
    *Journal of Crohn's and Colitis* [*PMID: 3533353*](https://pubmed.ncbi.nlm.nih.gov/35533353/)
-   The serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn's disease.\
    *Journal of Crohn's and Colitis* [*PMID: 37178692*](https://pubmed.ncbi.nlm.nih.gov/37178692/)
-   Breaking the therapeutic ceiling in drug development in ulcerative colitis.\
    *The Lancet Gastroenterology and Hepatology* [*PMID: 34019798*](https://pubmed.ncbi.nlm.nih.gov/34019798/)
-   Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\
    *Current Research in Pharmacology and Drug Discovery* [*PMID: 35146421*](https://pubmed.ncbi.nlm.nih.gov/35146421/)
-   Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\
    *Current Opinion in Pharmacology* [*PMID: 33039940*](https://pubmed.ncbi.nlm.nih.gov/33039940/)
-   Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\
    *Clinical Gastroenterology and Hepatology* [*PMID: 35850410*](https://pubmed.ncbi.nlm.nih.gov/35850410/)
-   Immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\
    *Alimentary Pharmacology & Therapeutics* [*PMID: 35315101*](https://pubmed.ncbi.nlm.nih.gov/35315101/)

## As a co-author

-   Tailoring multi-omics to inflammatory bowel diseases: all for one and one for all.\
    *Journal of Crohn's and Colitis* [*PMID: 35150242*](https://pubmed.ncbi.nlm.nih.gov/35150242/)

-   Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.\
    *European Journal of Gastroenterology and Hepatology* [*PMID: 36062494*](https://pubmed.ncbi.nlm.nih.gov/36062494/)

-   Translating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD.\
    *Inflammatory Bowel Diseases* [*PMID: 34751766*](https://pubmed.ncbi.nlm.nih.gov/34751766/)

-   The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.\
    *British Journal of Clinical Pharmacology* [*PMID: 33604964*](https://pubmed.ncbi.nlm.nih.gov/33604964/)

-   Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.\
    *Alimentary Pharmacology & Therapeutics [PMID: 35484689](https://pubmed.ncbi.nlm.nih.gov/35484689/)*
